Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda

AIDS

Volumn 23, Issue 7, 2009, Pages 845-852

  Eshleman, Susan H ^a   Laeyendecker, Oliver ^a,b   Parkin, Neil ^c   Huang, Wei ^c   Chappey, Colombe ^c   Paquet, Agnes C ^c   Serwadda, David ^d   Reynolds, Steven J ^a,b   Kiwanuka, Noah ^e   Quinn, Thomas C ^a,b   Gray, Ronald ^f   Wawer, Maria ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiretroviral drug; Hypersusceptibility; Phenotype; Resistance; Subtype; Uganda

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ARTICLE; ASSAY; BLOOD SAMPLING; CODON; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; UGANDA; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; ADULT; ANTIVIRAL RESISTANCE; DISEASE PREDISPOSITION; DRUG ADMINISTRATION; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MALE; MUTATION; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MUTATION; PHENOTYPE; UGANDA;

EID: 67649646720     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328327957a     Document Type: Article

References (27)

1. Rayfield MA, Downing RG, Baggs J, Hu DJ, Pieniazek D, Luo CC, et al. A molecular epidemiologic survey of HIV in Uganda. HIV variant working group. AIDS 1998;12:521-527.
2. Hu DJ, BaggsJ, Downing RG, Pieniazek D, Dorn J, Fridlund C, et al. Predominance of HIV-1 subtype A and D infections in Uganda. Emerg Infect Dis 2000;6:609-615.
3. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-130.
4. Kantor R, Katzenstein D. Drug resistance in nonsubtype B HIV-1. J Clin Virol 2004;29:152-159.
5. Church JD, Hudelson SE, Guay LA, Chen S, Hoover DR, Fiscus SA, et al. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res Hum Retroviruses 2007; 23:764-768.
6. Arroyo MA, Sateren WB, Serwadda D, Gray RH, Wawer MJ, Sewankambo NK, et al. Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr 2006;43:440-445.
7. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, HuangW, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
8. Flandre P, Chappey C, Marcelin AG, Ryan K, Maa JF, Bates M, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. J Infect Dis 2007;195:392-398.
9. Leitner T, Korber B, Daniels M, CalefC, Foley B. HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: Leitner T, Foley B, Hahn B, et al.editors. HIV sequence compendium 2005. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2005. pp. 41-48.
10. Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res 2004; 32:W654-W659.
11. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
12. Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000; 74:10269-10273.
13. ChoeSS, Stawiski E, Parkin NT. Interpretation of drug-susceptibility and replication-capacity results from subtype C HIV-1 protease/RT is not influenced by the subtype of the resistance test vector. Antiviral Therapy 2007;12:S118.
14. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997;71:5441- 5448.
15. Weidle PJ, Kityo CM, Mugyenyi P, Downing R, Kebba A, Pieniazek D, et al. Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr 2001; 26:495-500.
16. Deroo S, Robert I, Fontaine E, Lambert C, Plesseria JM, Arendt V, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS 2002; 16:2461-2467.
17. Agwale SM, Zeh C, Paxinos E, Odama L, Pienazek D, Wambebe C, et al. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 2006; 22: 22-26.
18. Fleury HJ, Toni T, Lan NT, Hung PV, Deshpande A, Recordon-Pinson P, et al. Susceptibility to antiretroviral drugs of CRF01-AE, CRF02-AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006; 22:357-366.
19. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in nonsubtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-3925.
20. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun- Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998;12: 1109-1111.
21. Abecasis AB, Deforche K, Bacheler LT, McKenna P, Carvalho AP, Gomes P, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir Ther 2006;11:581-589.
22. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31:215-220.
23. Poveda E, de Mendoza C, Parkin N, Choe S, Garcia-Gasco P, Corral A, Soriano V. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008;22:611-616.
24. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naive Ugandan adults. AIDS Res Hum Retroviruses 2000;16:807-813.
25. Gonzalez LM, Brindeiro RM, Tarin M, Calazans A, Soares MA, Cassol S,Tanuri A. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003;47:2817-2822.
26. McConnell MS, Stringer JSA, Kourtis AP, Weidle PJ, Eshleman SH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstetrics Gynecology 2007;197:S56- S63.
27. Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007;195:711-715.